| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss from continuing operations | -28,275 | -53,981 |
| Depreciation and amortization | 42,606 | 26,818 |
| Share based compensation | 33,404 | 22,141 |
| Foreign currency remeasurement impact | 2,466 | 2,165 |
| In-process research and development | 0 | 0 |
| Other | 1,500 | 693 |
| Accounts receivable | 55,641 | 11,486 |
| Inventory | -3,839 | -3,645 |
| Prepaid expenses and other current and non-current assets | 8,104 | 6,777 |
| Accounts payable | -6,332 | -5,223 |
| Accrued expenses | 11,501 | -8,200 |
| Deferred revenue | -2,815 | -2,815 |
| Other current and non-current liabilities | -9,111 | 1,525 |
| Net cash used in operating activities - continuing operations | -22,894 | -37,211 |
| Net cash used in operating activities - discontinued operations | 0 | 0 |
| Net cash used in operating activities | -22,894 | -37,211 |
| Proceeds from the sale and maturity of marketable debt securities | 241,175 | 134,553 |
| Purchase of marketable debt securities | 69,217 | 64,371 |
| Purchase of fixed assets | 375 | 235 |
| Purchase of intangible assets | 38,918 | 23,870 |
| Other | -66 | -63 |
| Payment of milestone | 0 | 0 |
| Net cash provided by investing activities | 132,731 | 46,140 |
| Payment of guaranteed minimum royalty | 1,575 | 1,050 |
| Repayment of 2025 convertible senior notes | 68,904 | - |
| Proceeds from exercise of stock options | 8,796 | 4,706 |
| Proceeds from issuances under the employee stock purchase plan | 1,537 | 1,537 |
| Net cash (used in) provided by financing activities | -60,146 | 5,193 |
| Effect of exchange rate changes on cash | 2,704 | 2,497 |
| Net increase (decrease) in cash and cash equivalents | 52,395 | 16,619 |
| Cash and cash equivalents at beginning of period | 58,535 | - |
| Cash and cash equivalents at end of period | 110,930 | - |
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX)